A retrospective comparison of allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic leukemia
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A retrospective comparison of allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic leukemia
Authors
Keywords
-
Journal
BONE MARROW TRANSPLANTATION
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-12-05
DOI
10.1038/s41409-018-0403-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Posttransplant chimeric antigen receptor therapy
- (2018) Melody Smith et al. BLOOD
- Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
- (2018) Margherita Norelli et al. NATURE MEDICINE
- CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
- (2018) Theodoros Giavridis et al. NATURE MEDICINE
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity
- (2017) Arnab Ghosh et al. NATURE MEDICINE
- TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance
- (2017) Yinmeng Yang et al. Science Translational Medicine
- Toxicities of chimeric antigen receptor T cells: recognition and management
- (2016) Jennifer N. Brudno et al. BLOOD
- Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia
- (2016) Yongxian Hu et al. CLINICAL CANCER RESEARCH
- CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
- (2016) Cameron J. Turtle et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells
- (2016) Partow Kebriaei et al. JOURNAL OF CLINICAL INVESTIGATION
- Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
- (2016) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors
- (2016) Daniel T. Harris et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
- (2015) Madan H. Jagasia et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Challenges and opportunities of allogeneic donor-derived CAR T cells
- (2015) Yinmeng Yang et al. CURRENT OPINION IN HEMATOLOGY
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- (2015) Daniel W Lee et al. LANCET
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
- (2015) David L. Porter et al. Science Translational Medicine
- Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia
- (2015) Hanren Dai et al. OncoImmunology
- ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells
- (2014) S. Guedan et al. BLOOD
- T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT
- (2014) Y. Luo et al. BLOOD
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
- (2014) M. L. Davila et al. Science Translational Medicine
- Understanding anti-leukemia responses to donor lymphocyte infusion
- (2014) Pavan Bachireddy et al. OncoImmunology
- Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study
- (2013) C. R. Y. Cruz et al. BLOOD
- Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation
- (2013) J. N. Kochenderfer et al. BLOOD
- CD3ζ-based chimeric antigen receptors mediate T cell activation viacis- andtrans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy
- (2013) J. S. Bridgeman et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Chronic GVHD is associated with inferior relapse risk irrespective of stem cell source among patients receiving transplantation from unrelated donors
- (2012) A Signori et al. BONE MARROW TRANSPLANTATION
- Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation
- (2011) Claire Roddie et al. EXPERT OPINION ON BIOLOGICAL THERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started